title: Liver disease in cystic fibrosis.
abstract: Cystic fibrosis-associated liver disease (CFLD) affects ca. 30% of patients. The CFLD is now considered the third cause of death, after lung disease and transplantation complications, in CF patients. Diagnostics, clinical assessment and treatment of CFLD have become a real challenge since a striking increase of life expectancy in CF patients has recently been observed. There is no elaborated "gold standard" in the diagnostic process of CFLD; clinical evaluation, laboratory tests, ultrasonography and liver biopsy are used. Clinical forms of CFLD are elevation of serum liver enzymes, hepatic steatosis, focal biliary cirrhosis, multilobular biliary cirrhosis, neonatal cholestasis, cholelithiasis, cholecystitis and micro-gallbladder. In children, CFLD symptoms mostly occur in puberty. Clinical symptoms appear late, when damage of the hepatobiliary system is already advanced. The CFLD is more common in patients with severe mutations of CFTR gene, in whom a complete loss of CFTR protein function is observed. CFLD, together with exocrine pancreatic insufficiency and meconium ileus, is considered a component of the severe CF phenotype. Treatment of CFLD should be complex and conducted by a multispecialist team (gastroenterologist, hepatologist, dietician, radiologist, surgeon). The main aim of the treatment is to prevent liver damage and complications associated with portal hypertension and liver cirrhosis. Ursodeoxycholic acid is used in the treatment of CFLD. There is no treatment of proven long-term efficacy in CFLD. Liver transplantation is a treatment of choice in end-stage liver disease.
authors.affiliation: Department of Paediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland.
authors.forename: Natalia
authors.initials: N
authors.lastname: Kobelska-Dubiel
authors.affiliation: Department of Paediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland.
authors.forename: Beata
authors.initials: B
authors.lastname: Klincewicz
authors.affiliation: Department of Paediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Cichy
keywords: cystic fibrosis; diagnostics; liver disease; treatment
references.citation: Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):585-92
references.pmid: 20955961
references.citation: J Pediatr. 2004 Sep;145(3):327-32
references.pmid: 15343185
references.citation: Dig Liver Dis. 2010 Jun;42(6):428-31
references.pmid: 20034860
references.citation: J Appl Genet. 2001;42(3):367-77
references.pmid: 14564043
references.citation: Paediatr Respir Rev. 2000 Jun;1(2):179-89
references.pmid: 12531112
references.citation: Hepatology. 2002 Dec;36(6):1374-82
references.pmid: 12447862
references.citation: Arch Dis Child. 1999 Aug;81(2):125-8
references.pmid: 10490518
references.citation: Gastroenterology. 2007 Nov;133(5):1592-602
references.pmid: 17916355
references.citation: Lancet. 2003 May 17;361(9370):1671-6
references.pmid: 12767731
references.citation: Hepatology. 1999 Nov;30(5):1151-8
references.pmid: 10534335
references.citation: J Hepatol. 1999 Nov;31(5):946-54
references.pmid: 10580595
references.citation: J Hepatol. 2004 Dec;41(6):920-5
references.pmid: 15582124
references.citation: Eur Respir J. 2011 Jul;38(1):59-69
references.pmid: 21233271
references.citation: Gastroenterology. 2007 Nov;133(5):1603-13
references.pmid: 17983806
references.citation: Paediatr Respir Rev. 2001 Dec;2(4):340-9
references.pmid: 12052306